Vistin Pharma Logo

Vistin Pharma

A leading global producer of Metformin Hydrochloride for the global healthcare market.

VISTN | OL

Overview

Corporate Details

ISIN(s):
NO0010734122
LEI:
5967007LIEEXZXFQY092
Country:
Norway
Address:
Postboks 6735 Etterstad, 0609 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Vistin Pharma is a specialized pharmaceutical company and a leading global producer of Metformin Hydrochloride, the standard first-line treatment for Type 2 diabetes. The company operates as a pure-play metformin supplier, producing both Active Pharmaceutical Ingredients (API) and Direct Compressible (DC) grades for the global healthcare market. As a dedicated European manufacturer, Vistin Pharma is positioned to supply a significant portion of the world's demand for this essential medicine, with a focus on high-quality and sustainable production.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-31 07:40
Investor Presentation
Vistin Pharma ASA: Third quarter and YTD 2025 financial results - Attachment: V…
English 1.7 MB
2025-10-31 07:40
Quarterly Report
Vistin Pharma ASA: Third quarter and YTD 2025 financial results - Attachment: V…
English 1.5 MB
2025-10-31 07:40
Earnings Release
Vistin Pharma ASA: Third quarter and YTD 2025 financial results
English 2.2 KB
2025-10-24 10:00
Report Publication Announcement
Vistin Pharma ASA: Invitation to Q3 2025 conference call
English 2.6 KB
2025-08-15 08:00
Interim Report
Vistin Pharma ASA: Second quarter and YTD 2025 financial results - Attachment: …
English 1.6 MB
2025-08-15 08:00
Investor Presentation
Vistin Pharma ASA: Second quarter and YTD 2025 financial results - Attachment: …
English 1.9 MB
2025-08-15 08:00
Earnings Release
Vistin Pharma ASA: Second quarter and YTD 2025 financial results
English 2.1 KB
2025-08-08 10:00
Regulatory News Service
Vistin Pharma ASA: Invitation to Q2 2025 conference call
English 1.6 KB
2025-06-04 08:00
Notice of Dividend Amount
Ex dividend NOK 1.25 today
English 330 bytes
2025-05-23 09:22
Report Publication Announcement
Financial calendar
English 464 bytes
2025-05-23 09:22
Report Publication Announcement
Finansiell kalender
Norwegian 448 bytes
2025-05-22 12:59
Post-Annual General Meeting Information
Vistin Pharma ASA: Minutes from the annual general meeting 2025
English 897.7 KB
2025-05-22 12:59
Post-Annual General Meeting Information
Vistin Pharma ASA: Minutes from the annual general meeting 2025
English 736 bytes
2025-05-22 09:56
Proxy Solicitation & Information Statement
Disclosure of voting rights at AGM in Vistin Pharma ASA
English 963 bytes
2025-05-07 13:30
Board/Management Information
Vistin Pharma ASA (VISTN): Update from the Election Committee
English 1.3 KB

Automate Your Workflow. Get a real-time feed of all Vistin Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vistin Pharma

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vistin Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

GI Innovation Inc. Logo
Develops fusion protein biologics for oncology, allergic, and metabolic diseases.
South Korea
358570
GILEAD SCIENCES, INC. Logo
Develops innovative medicines for life-threatening diseases in virology, oncology & inflammation.
United States of America
GILD
GlaxoSmithKline PLC Logo
A biopharmaceutical company developing vaccines and specialty medicines to prevent and treat disease.
United Kingdom
GSK
GL Pharm Tech Corp. Logo
Develops improved drugs and generics, and licenses proprietary drug formulation technologies.
South Korea
204840
GNI  Group Ltd. Logo
Biopharma firm developing novel drugs for cancer and inflammatory diseases using genetics.
Japan
2160
Goodwill Pharma Plc Logo
Integrated pharma CDMO developing Rx/OTC meds, supplements & devices for CEE markets.
Hungary
GWPH
Gossamer Bio, Inc. Logo
Clinical-stage biopharma developing inhaled therapies for rare pulmonary hypertension.
United States of America
GOSS
Grace Therapeutics, Inc. Logo
Develops improved drugs for rare neurological diseases using novel drug delivery technologies.
United States of America
GRCE
A biotech firm in biopharma, diagnostics, digital health, and consumer wellness products.
South Korea
005250
GREEN CROSS WellBeing Corporation Logo
Develops personalized nutrition solutions, from prescription injections to supplements & cosmetics.
South Korea
234690

Talk to a Data Expert

Have a question? We'll get back to you promptly.